Status:
RECRUITING
Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Asthma Acute
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Asthma is a common chronic bronchial disease affecting 300 million people worldwide. The disease can be severe when it is not managed properly or when it is not controlled by treatments. Asthma is cha...
Eligibility Criteria
Inclusion
- Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers:
- Consent form read, understood, approved and signed before any study procedure
- Membership of a social security scheme or beneficiary of such a scheme
- Patient aged over 18
- Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled exacerbation:
- \- Diagnosis of severe asthma confirmed by a respirologist at an expert centre
- Case asthma controlled:
- \- Asthma control confirmed by a lung specialist from an expert centre
- Case uncontrolled asthma excluding exacerbation:
- \- Uncontrolled asthma confirmed by a lung specialist from an expert centre
- Case uncontrolled asthma with exacerbation:
- \- Current exacerbation
Exclusion
- Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers:
- Person subject to a legal protection measure
- Vulnerable population: minors, persons under guardianship or trusteeship or persons deprived of their rights to liberty by court order.
- women with a known pregnancy
- Inability or refusal to comply with research requirements
- Active or weaned smoker \> 15 PA
- Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or opioids in the 10 days prior to inclusion
- Case patient with asthma:
- \- Coexistence of a chronic inflammatory disease other than asthma
- Case healthy volunteers:
- \- Coexistence of an inflammatory pathology
- Exclusion criteria:
- Cases asthma: Pregnancy during follow-up Cases healthy volunteers: Total IgE level greater than 100 kU/L (measured on the study sample)
Key Trial Info
Start Date :
September 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2030
Estimated Enrollment :
448 Patients enrolled
Trial Details
Trial ID
NCT06015256
Start Date
September 7 2023
End Date
September 1 2030
Last Update
April 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital NORD - AP-HM, Clinique des bronches, de l'allergie et du sommeil
Marseille, France, 13915